New drug cocktail aims to stop deadly esophageal cancer from coming back

This study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy and radiation can better control cancer and prevent it from returning in patients with locally advanced esophageal cancer that cannot be removed by surgery. The trial will enroll 46 patients who will receive the drug combination followed by a year of maintenance therapy with the immunotherapy drug. Researchers will measure how long patients live without their cancer getting worse and monitor side effects.